Investing.com - Mirum Pharmaceuticals (NASDAQ: MIRM) reported second quarter EPS of $-1.94, $1.22 worse than the analyst estimate of $-0.72. Revenue for the quarter came in at $37.5M versus the consensus estimate of $30.23M.
Mirum Pharmaceuticals's stock price closed at $24.88. It is down -5.15% in the last 3 months and down -4.49% in the last 12 months.
Mirum Pharmaceuticals saw 3 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Mirum Pharmaceuticals's stock price’s past reactions to earnings here.
According to InvestingPro, Mirum Pharmaceuticals's Financial Health score is "fair performance".
Check out Mirum Pharmaceuticals's recent earnings performance, and Mirum Pharmaceuticals's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar